GLP-1 Analogues Market Forecast: USD 471.1 Billion by 2032 With a 33.2% CAGR | MarketsandMarkets
GLP-1 Analogues Market Forecast: USD 471.1 Billion by 2032 With a 33.2% CAGR | MarketsandMarkets
CHICAGO, July 11, 2024 /PRNewswire/ -- The global GLP-1 analogues market is poised for substantial growth, projected to expand from USD 47.4 billion in 2024 to USD 471.1 billion by 2032, at a robust CAGR of 33.2%. Key drivers include the drugs' efficacy in managing diabetes and obesity, driving high demand and clinical research advancements. The market is dominated by two major players, Novo Nordisk A/S and Eli Lilly and Company, creating significant entry barriers. Opportunities lie in expanding therapeutic applications beyond diabetes to include conditions like NASH and Alzheimer's disease. However, challenges such as patient non-adherence and the dominance of injectable formats hinder market growth. North America leads in market share, supported by accessibility and demand for GLP-1 analogues. Key players like Novo Nordisk, Eli Lilly, Sanofi, and AstraZeneca are pivotal in shaping market dynamics through extensive R&D and strategic expansions.
芝加哥，2024年7月11日 /PRNewswire/ — 全球 GLP-1 類似物市場有望實現大幅增長，預計將從2024年的474美元擴大到2032年的4711美元，複合年增長率爲33.2％。關鍵驅動因素包括這些藥物在控制糖尿病和肥胖方面的功效，推動了高需求和臨床研究的進展。該市場由兩個主要參與者主導，即諾和諾德A/S和禮來公司，這創造了巨大的進入壁壘。機會在於將治療應用擴展到糖尿病以外，將NASH和阿爾茨海默氏病等疾病包括在內。但是，患者不依從和注射形式的主導地位等挑戰阻礙了市場增長。在 GLP-1 類似物的可及性和需求的支持下，北美的市場份額處於領先地位。諾和諾德、禮來、賽諾菲和阿斯利康等主要參與者在通過廣泛的研發和戰略擴張塑造市場動態方面起着至關重要的作用。